← Back to Home

Engaging T Cells Against Leukemia: CLN-049 Begins a Phase 2 Trial That Could Support a Regulatory Application

CLN-049 targets the FLT3 protein in an effort to direct immune attacks beyond the limits of mutation status. The first patient has been dosed in the new trial; the next questions are which dose is appropriate and whether efficacy can be sustained.

By SURL BioNews

When acute myeloid leukemia (AML) relapses or does not respond to treatment, patients often have limited options for what comes next. Cullinan Therapeutics announced on October 8 that the first patient had been dosed in a Phase 2 trial of the investigational drug CLN-049, which will further test a strategy that uses T cells to attack leukemia cells. The company hopes the study will provide evidence to support a future regulatory application, but the announcement concerns the start of the trial, with no efficacy results yet available from this phase.

CLN-049 is an FLT3×CD3 bispecific antibody: one end recognizes the FLT3 protein on the surface of leukemia cells, while the other binds to CD3 on T cells, aiming to bring immune cells close to their targets. According to the company announcement and RTTNews reporting, it can bind both mutated and unmutated FLT3, so its design does not require an FLT3 mutation for activity. However, recognizing both forms of the protein does not mean that all patients with AML can benefit; its targets remain leukemia cells that express FLT3.

The new study enrolls patients with relapsed or refractory AML who have received up to two prior lines of therapy. It will first evaluate two target doses, then proceed to a single-arm expansion phase using the selected recommended Phase 2 dose. This approach places dose selection before expanded enrollment, giving researchers an opportunity to weigh drug activity against tolerability.

Cullinan said the trial is moving forward following an end-of-Phase 1 meeting with the U.S. Food and Drug Administration (FDA), and described it as a potentially registrational study. That designation remains contingent on subsequent evidence. In particular, the single-arm expansion phase has no concurrent control group, so interpretation of efficacy must account for differences in patient characteristics and prior treatments. The start of the trial alone cannot establish that the new drug is superior to existing options.

The study also includes an exploratory cohort evaluating CLN-049 in newly diagnosed AML with TP53 mutations. This extends the study to another group of patients with limited treatment options, but exploratory results primarily help identify directions for further research. Whether they can support broader use will require corresponding clinical evidence.

Meanwhile, the company is initiating another Phase 1/2 study evaluating CLN-049 in combination with azacitidine and venetoclax in patients with newly diagnosed AML. This is a different treatment setting from the monotherapy study in relapsed or refractory AML, and the efficacy and safety of the combination must also be evaluated separately.

The next nearer-term update is from the Phase 1 dose-escalation study, which the company expects to release in December 2026. This announcement did not provide the planned enrollment, primary endpoint, or completion timeline for the new Phase 2 trial. For patients, the crucial answers still lie in the subsequent data: how durable the disease control from this immune attack can be, and whether the treatment burden is acceptable.

References

  1. Cullinan Therapeutics via GlobeNewswire
  2. RTTNews